TD Cowen Lowers Danaher (NYSE:DHR) Price Target to $245.00

Danaher (NYSE:DHR) had its price target dropped by analysts at TD Cowen from $270.00 to $245.00 in a research note issued to investors on Monday,MarketScreener reports. The firm presently has a “buy” rating on the conglomerate’s stock. TD Cowen’s price target would indicate a potential upside of 23.38% from the stock’s current price.

A number of other equities research analysts have also issued reports on the company. Argus set a $265.00 price target on Danaher in a research report on Wednesday, January 14th. Wolfe Research reduced their price target on Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Danaher in a research report on Thursday, January 29th. The Goldman Sachs Group reduced their price target on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Friday, March 27th. Eighteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $247.35.

Danaher Price Performance

DHR stock opened at $198.58 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.87 and a quick ratio of 1.51. The firm has a market capitalization of $140.54 billion, a P/E ratio of 39.40, a P/E/G ratio of 2.66 and a beta of 0.95. The business’s 50-day moving average is $200.12 and its two-hundred day moving average is $214.88. Danaher has a 1 year low of $180.03 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 27th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. The company had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.Danaher’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.14 EPS. Analysts anticipate that Danaher will post 7.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president owned 5,099 shares of the company’s stock, valued at approximately $1,060,642.99. This trade represents a 20.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Danaher

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tyche Wealth Partners LLC purchased a new position in Danaher during the 3rd quarter worth approximately $462,000. Bank Pictet & Cie Europe AG grew its stake in shares of Danaher by 25.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate’s stock valued at $83,895,000 after purchasing an additional 74,301 shares during the last quarter. Lockheed Martin Investment Management Co. grew its stake in shares of Danaher by 49.4% in the 3rd quarter. Lockheed Martin Investment Management Co. now owns 25,340 shares of the conglomerate’s stock valued at $5,024,000 after purchasing an additional 8,380 shares during the last quarter. Johnson Investment Counsel Inc. grew its stake in shares of Danaher by 2.9% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 664,705 shares of the conglomerate’s stock valued at $131,784,000 after purchasing an additional 18,744 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. grew its stake in shares of Danaher by 4.6% in the 3rd quarter. Resona Asset Management Co. Ltd. now owns 513,288 shares of the conglomerate’s stock valued at $100,071,000 after purchasing an additional 22,595 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Beckman Coulter Diagnostics (a Danaher unit) received CE mark for the Access MeMed BV assay, a high-throughput host‑response test that differentiates bacterial vs. viral infections in ~20 minutes — a commercial approval that could support diagnostics revenue and adoption in Europe. Beckman Coulter Diagnostics Earns CE Mark
• Positive Sentiment: Sector tailwind: cell therapy and regenerative medicine markets are forecast to grow strongly (high single- to double-digit CAGR), supporting long-term demand for life-science tools and services that benefit parts of Danaher’s portfolio. Cell Therapy Market Growth
• Neutral Sentiment: Danaher confirmed an upcoming earnings release next Tuesday — investors will focus on revenue growth, margin commentary and guidance for reaction. Danaher to Release Earnings
• Neutral Sentiment: Market commentary pieces are tracking recent share moves and volume, but contain no new material company guidance — useful for sentiment context but not new fundamentals. Share Price Commentary
• Negative Sentiment: Analysts trimmed price targets this week: TD Cowen cut its target to $245 (from $270) but kept a Buy rating, and Goldman lowered its target to $230 (from $265) while also retaining Buy — lower targets reduce implied upside even if convictions remain. TD Cowen Adjusts Price Target Goldman Target Cut
• Negative Sentiment: Pre-earnings analyst commentary (Zacks/Yahoo) suggests Danaher lacks the setup that typically yields an earnings beat in the coming report — if results or guidance disappoint, the stock could underperform near term. Earnings Beat Odds

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.